Roche announced the commercial availability of the cobas HIV-1, HCV
and HCV Genotyping (GT) assays in countries accepting the CE mark.
These new molecular diagnostic assays increase the available menu on
the cobas 4800 System, further improving efficiency and flexibility that
allows laboratories to deliver results for rapid clinical decisions.
The new virology assays offer the latest generation of performance
with dual target technology for HIV-1 and dual probe technology for HCV.
All of the new virology assays can run simultaneously on the cobas 4800
System, with optimized sample processing volumes for streamlining
workflow that increases flexibility for patient sample management. With
these additions, the cobas 4800 System now has a menu of 12 high medical
value IVD assays, making it the ideal solution for a highly efficient
laboratory.
The assays launched today will be followed in the coming months by the
cobas HBV Test, which will complete the portfolio of viral load
monitoring and genotyping assays for the cobas 4800 System.
